Neuroenhancement strategies for psychiatric disorders: rationale, status quo and perspectives

  title={Neuroenhancement strategies for psychiatric disorders: rationale, status quo and perspectives},
  author={Claus Normann and Christoph Nissen and Lukas Frase},
  journal={European Archives of Psychiatry and Clinical Neuroscience},
With the growing mechanistic understanding of higher brain functions like learning and memory, vigilance and social cognition, new pharmacological approaches for the treatment of psychiatric disorders arise. Substances used as neuroenhancers for the improvement of cognitive or emotional functions in healthy subjects might provide novel pharmacological opportunities in psychiatry. Intriguingly, drugs like modafinil, d-cycloserine or oxytocin have shown significant improvements in key symptoms in… Expand
Can pharmacological enhancement of the placebo effect be a novel therapy for working memory impairments?
In a randomised controlled clinical trial it is demonstrated that while working memory performance is not influenced by expectancy per se when it is given in conjunction with oxytocin performance in terms of accuracy can be significantly enhanced following positive expectancy induction and impaired following negative expectancy induction. Expand
Transcranial Laser Stimulation as Neuroenhancement for Attention Bias Modification in Adults with Elevated Depression Symptoms
The beneficial effects of ABM on depression symptoms may be enhanced when paired with adjunctive interventions such as right prefrontal LLLT; however, cognitive response to ABM likely moderates the impact of neuroenhancement. Expand
Oxytocin Enhancement of the Placebo Effect May Be a Novel Therapy for Working Memory Impairments
It is demonstrated for the first time that adjunct oxytocin treatment induces expectancy-driven enhancement of working memory in patients with high baseline performance and without sleep deprivation. Expand
Selected issues of the DGPPN Congress in 2011
This issue deals with a wide and multifocal thematic range of interesting scientific contents presented at the DGPPN Congress in November 2011, including insight into increased utilization of psychiatric and psychosomatic disciplines in both in and outpatient treatment. Expand
Preserving the Art and Science of Psychotherapy for Advance Practice Psychiatric Mental Health Nurses
  • Ann Caughill
  • Psychology, Medicine
  • Issues in mental health nursing
  • 2016
This article reviews literature on the topic of psychotherapy and a call for a renewed emphasis on this mode of treatment for psychiatric mental health advance practice nurses. Expand
Use of medicines and dietary supplements among Bridge players in two world-class tournaments
Professional Bridge players’ demographic and health-related characteristics indicate to a different pattern of drug use than “physical” athletes normally considered under the World Anti-Doping Code. Expand


Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.
These pilot data provide initial support for the use of acute dosing of DCS as an adjunct to exposure-based psychotherapy to accelerate the associative learning processes that contribute to correcting psychopathology. Expand
Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.
Modafinil combined with an SSRI at treatment initiation may enhance the onset and degree of symptom benefit in patients with MDD and fatigue. Expand
Theory of mind deficits in chronically depressed patients
Compared the ToM performance of chronically depressed patients with a healthy control group and to clarify the relation of ToM to other cognitive functions, patients with chronic depression present significant deficits in "reading” social interactions, which may be associated with general cognitive impairments. Expand
A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression.
These data suggest that adjunctive modafinil at doses of 100-200 mg a day may improve depressive symptoms in patients with bipolar disorder. Expand
Modafinil Augmentation of SSRI Therapy in Patients with Major Depressive Disorder and Excessive Sleepiness and Fatigue: A 12-Week, Open-label, Extension Study
Twelve weeks of modafinil augmentation relieved excessive sleepiness, reduced fatigue, and improved patients' overall clinical condition, including mood. Expand
Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.
Modafinil rapidly improved fatigue and daytime wakefulness, with significantly greater mean improvements from baseline than placebo in fatigue (FSS) scores at week 2 and sleepiness (ESS) Scores at week 1; the differences between modaf inil and placebo at week 6 were not statistically significant. Expand
Modafinil: preclinical, clinical, and post-marketing surveillance--a review of abuse liability issues.
Initial evidence suggests that modafinil has limited potential for large-scale abuse, and evidence from preclinical in vitro and in vivo studies, human laboratory studies, and post-marketing experiences examining the potential abuse liability of modafInil were reviewed. Expand
A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
Modafinil is a well-tolerated and potentially effective augmenting agent for SSRI partial responders with fatigue and sleepiness despite selective serotonin reuptake inhibitor (SSRI) monotherapy. Expand
Oxytocin Enhances Amygdala-Dependent, Socially Reinforced Learning and Emotional Empathy in Humans
Findings provide the first demonstration that OT can facilitate amygdala-dependent, socially reinforced learning and emotional empathy in men, as well as two patients with selective bilateral damage to the amygdala. Expand
Study of the addictive potential of modafinil in naive and cocaine-experienced rats
The results suggest that modafinil does not possess an addictive potential in naive individuals, and would be behaviorally distinct from classical central nervous system stimulants which are known to alter cocaine-induced effects. Expand